• Potential for weight loss^*
• Comparable rate of hypoglycaemia
• Transient gastrointestinal adverse reactions
  - In clinical trials, the majority of gastrointestinal events were reported during the first 2 to 3 days after the initial dose and declined with subsequent doses

*Trulicity is not indicated for weight loss, and weight change was a secondary endpoint in clinical trials.

• Trulicity 1.5 mg was associated with sustained weight reduction* over the duration of studies (from baseline to final time point -0.35 kg to -2.90 kg)
• In AWARD-6, although both treatment groups experienced weight loss,* the amount of weight loss was significantly greater with liraglutide 1.8 mg

All n values refer to intent-to-treat population.

In AWARD-1, AWARD-2, and AWARD-5, additional groups received Trulicity 0.75 mg, which is the recommended dose for monotherapy. For potentially vulnerable populations, such as patients ≥75 years of age, 0.75 mg once weekly can be considered as a starting dose.

• The rate of documented symptomatic hypoglycaemia (episodes/patient/year) was 0.12 with Trulicity 1.5 mg and 0.29 with liraglutide 1.8 mg
• No cases of severe hypoglycaemia were observed
  
• 26-week active-controlled phase III noninferiority study
• Treatment was added to background therapy with metformin
• Primary endpoint met: noninferiority of Trulicity 1.5 mg vs liraglutide 1.8 mg in HbA1c reduction from baseline to 26 weeks (-1.42% vs -1.36%, P<.001 for noninferiority)
• Data shown are for secondary endpoint
• All n values refer to intent-to-treat population

*Documented symptomatic hypoglycaemia and blood glucose ≤3.9 mmol/L.

Please be aware: Patients receiving Trulicity in combination with a sulphonylurea or prandial insulin may have an increased risk of hypoglycaemia. The risk may be lowered by reducing the dose of sulphonylurea or insulin.

• Gastrointestinal side effects are typical of the GLP-1 receptor agonist class²
• Gastrointestinal side effects in clinical trials were usually mild to moderate¹
• In clinical pharmacology studies, most gastrointestinal side effects occurred during the first 2 to 3 days after the initial dose, and incidence declined with subsequent doses¹
• In clinical trials, less than 2% of Trulicity-treated patients withdrew due to nausea¹
• Incidence of nausea was comparable with Trulicity 1.5 mg and liraglutide 1.8 mg³
  
• 26-week active-controlled phase III noninferiority study
• Treatment was added to background therapy with metformin
• Patients randomised to liraglutide started at 0.6 mg/day in week 1, then were uptitrated to 1.2 mg/day in week 2 and to 1.8 mg/day in week 3
• Primary endpoint met: noninferiority of Trulicity 1.5 mg vs liraglutide 1.8 mg in HbA1c reduction from baseline to 26 weeks (-1.42% vs -1.36%, P<.001 for noninferiority)
• Data shown are for secondary endpoint
• All n values refer to intent-to-treat population

Review the abbreviated prescribing information for Trulicity.